Table 3.
Baseline characteristics of the ISS T-002 study participants by treatment groups
| Tat 7.5 μg, 3x | Tat 7.5 μg, 5x | Tat 30 μg, 3x | Tat 30 μg, 5x | |
|---|---|---|---|---|
| ( n = 40) | ( n = 40) | ( n = 38) | ( n = 37) | |
| Age | ||||
| Mean ± s.d.a | 40 ± 7 | 41 ± 6 | 43 ± 5 | 42 ± 8 |
| Range | 24-54 | 29-55 | 33-55 | 26-54 |
| Gender | ||||
| Male | 73% | 90% | 79% | 92% |
| Female | 27% | 10% | 21% | 8% |
| CD4 + nadir (cells/μl) | ||||
| Mean ± s.d. | 287 ± 74 | 321 ± 139 | 337 ± 165 | 285 ± 136 |
| Range | 97-450 | 76-699 | 15-846 | 14-585 |
| CD4 + (cells/μl) | ||||
| Mean ± s.d. | 660 ± 216 | 644 ± 233 | 617 ± 214 | 632 ± 222 |
| Range | 293-1490 | 214-1382 | 212-1362 | 286-1250 |
| CD4 + (%) | ||||
| Mean ± s.d. | 34 ± 7 | 33 ± 7 | 33 ± 7 | 33 ± 10 |
| Range | 22-53 | 20-46 | 19-47 | 14-61 |
| Years from diagnosis of HIV | ||||
| Mean ± s.d. | 8 ± 6 | 10 ± 6 | 10 ± 7 | 9 ± 7 |
| Range | 1-21 | 2-25 | 1-23 | 1-24 |
| Years from HAART initiation | ||||
| Mean ± s.d. | 5 ± 4 | 6 ± 4 | 7 ± 5 | 7 ± 5 |
| Range | 0-19 | 0-19 | 0-18 | 1-17 |
| Current HAART regimen | ||||
| NNRTI-based or NRTI | 58% | 75% | 66% | 76% |
| PI-based | 42% | 25% | 34% | 24% |
n indicates the number of evaluable individuals; aStandard deviation.
No significant differences were detected among treatment groups at baseline.